JPH04501065A - 改良されたバキュロウイルス発現ベクター - Google Patents

改良されたバキュロウイルス発現ベクター

Info

Publication number: JPH04501065A
Authority: JP; Japan
Prior art keywords: promoter; vector; gene; modified; baculovirus
Prior art date: 1989-05-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2508753A

Other languages

English (en)

Japanese (ja)

Inventor

ミラー，ロイス　ケイ．

Original Assignee

ユニバーシティオブジョージアリサーチファウンデーションインコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-05-17

Filing date

1990-05-17

Publication date

1992-02-27

1990-05-17 Application filed by ユニバーシティオブジョージアリサーチファウンデーションインコーポレイテッド filed Critical ユニバーシティオブジョージアリサーチファウンデーションインコーポレイテッド

1992-02-27 Publication of JPH04501065A publication Critical patent/JPH04501065A/ja

Status Pending legal-status Critical Current

Links

241000701447 unidentified baculovirus Species 0.000 title claims description 38
239000013604 expression vector Substances 0.000 title claims description 23
230000001976 improved effect Effects 0.000 title description 4
108090000623 proteins and genes Proteins 0.000 claims description 182
230000014509 gene expression Effects 0.000 claims description 114
239000013612 plasmid Substances 0.000 claims description 98
239000013598 vector Substances 0.000 claims description 70
241000700605 Viruses Species 0.000 claims description 60
102000004169 proteins and genes Human genes 0.000 claims description 35
238000000034 method Methods 0.000 claims description 30
241000238631 Hexapoda Species 0.000 claims description 22
238000011144 upstream manufacturing Methods 0.000 claims description 19
108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 12
238000013518 transcription Methods 0.000 claims description 11
230000035897 transcription Effects 0.000 claims description 11
238000003780 insertion Methods 0.000 claims description 9
230000037431 insertion Effects 0.000 claims description 9
108700009124 Transcription Initiation Site Proteins 0.000 claims description 8
230000004913 activation Effects 0.000 claims description 5
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims description 5
230000008488 polyadenylation Effects 0.000 claims description 4
230000001105 regulatory effect Effects 0.000 claims description 4
230000006154 adenylylation Effects 0.000 claims description 3
230000000977 initiatory effect Effects 0.000 claims description 3
241001203868 Autographa californica Species 0.000 claims 1
241000256135 Chironomus thummi Species 0.000 claims 1
241000275031 Nica Species 0.000 claims 1
101710182846 Polyhedrin Proteins 0.000 description 36
210000004027 cell Anatomy 0.000 description 27
238000010367 cloning Methods 0.000 description 25
238000010276 construction Methods 0.000 description 22
239000013603 viral vector Substances 0.000 description 20
238000010586 diagram Methods 0.000 description 18
208000015181 infectious disease Diseases 0.000 description 17
108020004414 DNA Proteins 0.000 description 15
230000003612 virological effect Effects 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
125000003729 nucleotide group Chemical group 0.000 description 12
238000012546 transfer Methods 0.000 description 11
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
230000008569 process Effects 0.000 description 10
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 9
101150055766 cat gene Proteins 0.000 description 9
230000004481 post-translational protein modification Effects 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
230000000694 effects Effects 0.000 description 8
230000010076 replication Effects 0.000 description 7
230000014616 translation Effects 0.000 description 7
230000008901 benefit Effects 0.000 description 6
108010086093 Mung Bean Nuclease Proteins 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
108700008625 Reporter Genes Proteins 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
230000006801 homologous recombination Effects 0.000 description 5
238000002744 homologous recombination Methods 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
238000012552 review Methods 0.000 description 5
101710163270 Nuclease Proteins 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
210000000234 capsid Anatomy 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000010353 genetic engineering Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
230000034303 cell budding Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
210000003000 inclusion body Anatomy 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
239000011269 tar Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
241001367049 Autographa Species 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
206010048685 Oral infection Diseases 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
101150036080 at gene Proteins 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000000869 mutational effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000238421 Arthropoda Species 0.000 description 1
108700003860 Bacterial Genes Proteins 0.000 description 1
241000537222 Betabaculovirus Species 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
241001070941 Castanea Species 0.000 description 1
235000014036 Castanea Nutrition 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
235000009852 Cucurbita pepo Nutrition 0.000 description 1
241000219104 Cucurbitaceae Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000255925 Diptera Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108091092566 Extrachromosomal DNA Proteins 0.000 description 1
101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
235000000177 Indigofera tinctoria Nutrition 0.000 description 1
241000726306 Irus Species 0.000 description 1
241000255777 Lepidoptera Species 0.000 description 1
206010027336 Menstruation delayed Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
241000256259 Noctuidae Species 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000014592 Panops Species 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
102100037204 Sal-like protein 1 Human genes 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
240000004922 Vigna radiata Species 0.000 description 1
235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003491 array Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000010951 brass Substances 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000002468 fat body Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
102000017941 granulin Human genes 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000012447 hatching Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940097275 indigo Drugs 0.000 description 1
COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
YIEDSISPYKQADU-UHFFFAOYSA-N n-acetyl-n-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]acetamide Chemical compound C1=C(C)C(N(C(C)=O)C(=O)C)=CC=C1N=NC1=CC=CC=C1C YIEDSISPYKQADU-UHFFFAOYSA-N 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000007065 protein hydrolysis Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
239000002795 scorpion venom Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000011282 treatment Methods 0.000 description 1
241000701451 unidentified granulovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Genetics & Genomics (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Virology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP2508753A 1989-05-17 1990-05-17 改良されたバキュロウイルス発現ベクター Pending JPH04501065A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35384789A	1989-05-17	1989-05-17
US353,847		1989-05-17

Publications (1)

Publication Number	Publication Date
JPH04501065A true JPH04501065A (ja)	1992-02-27

Family

ID=23390826

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2508753A Pending JPH04501065A (ja)	1989-05-17	1990-05-17	改良されたバキュロウイルス発現ベクター

Country Status (5)

Country	Link
EP (1)	EP0426840A1 (fr)
JP (1)	JPH04501065A (fr)
AU (1)	AU631223B2 (fr)
CA (1)	CA2033070A1 (fr)
WO (1)	WO1990014428A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9106185D0 (en) *	1991-03-22	1991-05-08	Wellcome Found	Biological control agents
US5593669A (en) *	1992-04-29	1997-01-14	Boyce Thompson Institute For Plant Research, Inc.	Stable pre-occluded virus particle
DE69333051T2 (de) *	1992-04-29	2004-04-29	Boyce Thompson Institute For Plant Research, Inc.	Mundinfektion der insektlarven mit prä-okkludierten bakuloviruspartikeln
US6090379A (en) *	1992-04-29	2000-07-18	Boyce Thompson Institute For Plant Research, Inc.	Stable pre-occluded virus particle for use in recombinant protein production and pesticides
FR2715664B1 (fr) *	1994-01-31	1996-04-12	Proteine Performance Sa	Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US7026156B1 (en)	1999-02-04	2006-04-11	The University Of Georgia Research Foundation, Inc.	Diagnostic and protective antigen gene sequences of ichthyophthirius
US6846481B1 (en)	1999-02-04	2005-01-25	University Of Georgia Research Foundation, Inc.	Recombinant expression of heterologous nucleic acids in protozoa
US7326568B2 (en)	1999-02-04	2008-02-05	University Of Georgia Research Foundation, Inc.	Recombinant expression of heterologous nucleic acids in protozoa
BRPI0507169A (pt)	2004-02-02	2007-06-26	Ambrx Inc	polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7632924B2 (en)	2004-06-18	2009-12-15	Ambrx, Inc.	Antigen-binding polypeptides and their uses
WO2006091231A2 (fr)	2004-07-21	2006-08-31	Ambrx, Inc.	Polypeptides biosynthetiques obtenus a partir d'acides amines codes par voie non naturelle
EP1836298B1 (fr)	2004-12-22	2012-01-18	Ambrx, Inc.	Compositions de synthetase d'aminoacyl-arnt et utilisations correspondantes
EP2399893B1 (fr)	2004-12-22	2018-08-15	Ambrx, Inc.	Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations
CN103520735B (zh)	2004-12-22	2015-11-25	Ambrx公司	包含非天然编码的氨基酸的人生长激素配方
EP1836316A4 (fr)	2004-12-22	2009-07-22	Ambrx Inc	Procédés pour l'expression et la purification d'hormone de croissance humaine recombinante
BRPI0519430A2 (pt)	2004-12-22	2009-02-10	Ambrx Inc	hormânio do crescimento humano modificado
AU2006255122B2 (en)	2005-06-03	2010-10-21	Ambrx, Inc.	Improved human interferon molecules and their uses
AU2005335491B2 (en)	2005-08-18	2010-11-25	Ambrx, Inc.	Compositions of tRNA and uses thereof
DK2339014T3 (en)	2005-11-16	2015-07-20	Ambrx Inc	Methods and compositions comprising non-natural amino acids
JP5399906B2 (ja)	2006-09-08	2014-01-29	アンブルックス，インコーポレイテッド	脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
EP2064333B1 (fr)	2006-09-08	2014-02-26	Ambrx, Inc.	Transcription d'arnt suppresseur dans des cellules de vertébrés
CN106008699A (zh)	2006-09-08	2016-10-12	Ambrx公司	经修饰的人类血浆多肽或Fc骨架和其用途
CN107501407B (zh)	2007-03-30	2022-03-18	Ambrx公司	经修饰fgf-21多肽和其用途
US8114630B2 (en)	2007-05-02	2012-02-14	Ambrx, Inc.	Modified interferon beta polypeptides and their uses
MX2010005317A (es)	2007-11-20	2010-06-02	Ambrx Inc	Polipeptidos de insulina modificados y sus usos.
MX344166B (es)	2008-02-08	2016-12-07	Ambrx Inc	Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh)	2008-07-23	2011-08-17	Ambrx公司	经修饰的牛g-csf多肽和其用途
BR122012024318A2 (pt)	2008-09-26	2019-07-30	Ambrx, Inc.	Polipeptídeos modificados de eritropoetina animal e seus usos
AU2009296267B2 (en)	2008-09-26	2013-10-31	Ambrx, Inc.	Non-natural amino acid replication-dependent microorganisms and vaccines
MX349301B (es)	2009-12-21	2017-07-21	Ambrx Inc	Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012015597A2 (pt)	2009-12-21	2017-01-31	Ambrx Inc	peptídeos de somatotropina suínos modificados e seus usos
US9567386B2 (en)	2010-08-17	2017-02-14	Ambrx, Inc.	Therapeutic uses of modified relaxin polypeptides
EA030886B1 (ru)	2010-08-17	2018-10-31	Амбркс, Инк.	Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
CN114805532A (zh)	2014-10-24	2022-07-29	百时美施贵宝公司	修饰的fgf-21多肽及其用途
PE20191716A1 (es)	2017-02-08	2019-12-05	Bristol Myers Squibb Co	Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CN116042720B (zh) *	2023-02-14	2025-09-02	中国科学院武汉病毒研究所	一种转运载体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2631974B1 (fr) *	1988-05-31	1992-12-11	Agronomique Inst Nat Rech	Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
WO1990010078A1 (fr) *	1989-02-23	1990-09-07	University Of Ottawa	Systeme ameliore d'expression de baculovirus capable de produire des proteines de genes etrangers en grande quantite

1990
- 1990-05-17 JP JP2508753A patent/JPH04501065A/ja active Pending
- 1990-05-17 CA CA 2033070 patent/CA2033070A1/fr not_active Abandoned
- 1990-05-17 AU AU58207/90A patent/AU631223B2/en not_active Ceased
- 1990-05-17 WO PCT/US1990/002814 patent/WO1990014428A1/fr not_active Ceased
- 1990-05-17 EP EP19900909228 patent/EP0426840A1/fr not_active Ceased

Also Published As

Publication number	Publication date
CA2033070A1 (fr)	1990-11-18
WO1990014428A1 (fr)	1990-11-29
AU631223B2 (en)	1992-11-19
AU5820790A (en)	1990-12-18
EP0426840A1 (fr)	1991-05-15

Publication	Publication Date	Title
JPH04501065A (ja)	1992-02-27	改良されたバキュロウイルス発現ベクター
US5244805A (en)	1993-09-14	Baculovirus expression vectors
JP3076833B2 (ja)	2000-08-14	修飾されたバクロウイルス、その製造方法及び該バクロウイルスから得られる発現ベクター
US5516657A (en)	1996-05-14	Baculovirus vectors for expression of secretory and membrane-bound proteins
JP3183877B2 (ja)	2001-07-09	修飾バキュロウイルス、その調整方法及びそれの形質発現ベクターとしての適用
US5169784A (en)	1992-12-08	Baculovirus dual promoter expression vector
AU736334B2 (en)	2001-07-26	Insect expression vectors
AU647190B2 (en)	1994-03-17	Expression system
CA2301179A1 (fr)	1999-03-04	Chromosomes artificiels de baculovirus et procedes d'utilisation
US12385014B2 (en)	2025-08-12	Baculovirus expression system
Horiuchi et al.	1987	High-level expression of the human-α-interferon gene through the use of an improved baculovirus vector in the silkworm, Bombyx mori
JPH05508538A (ja)	1993-12-02	馬ヘルペスウィルス―４　ｔｋ￣ワクチン
JPH0365191A (ja)	1991-03-20	スフェロイジン単離ｄｎａおよび組み換え昆虫ポックスウィルス発現ベクター
IE60285B1 (en)	1994-06-29	Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom
Wu et al.	2004	Expression of human VEGF165 in silkworm (Bombyx mori L.) by using a recombinant baculovirus and its bioactivity assay
Guo et al.	2005	Silk gland specific secretory expression of egfp gene in silkworm Bombyx mori with rAcMNPV system
US6037150A (en)	2000-03-14	Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
US6106825A (en)	2000-08-22	Entomopoxvirus-vertebrate gene delivery vector and method
TW200521137A (en)	2005-07-01	Protein isolation
KR100270928B1 (ko)	2001-02-01	누에 핵다각체병 바이러스 p10 유전자를 이용한 전이 벡터 및 제조방법
CN118813548B (zh)	2024-12-20	一种利用BTI-Tn-5B1-4细胞表达重组人白蛋白的方法及培养基
US20260125656A1 (en)	2026-05-07	Baculovirus expression system
KR102070940B1 (ko)	2020-04-01	당단백질 호르몬 생산용 조성물
WO2000050616A2 (fr)	2000-08-31	Sequences permettant d'ameliorer l'efficacite de la secretion de proteines non secretees de cellules de mammiferes et d'insectes
Hong et al.	2001	Comparison of promoter activity of the p10 gene between Bombyx mori nucleopolyhedrovirus variants